Saturday, 14th February 38th Lorne Cancer Conference 2026

• Restoring Tumor Suppressor Function in TP53 Y220C–Mutant Cancers - Masha V Poyurovsky
• Accelerating prediction of tumor vulnerabilities using precision functional genomics - Jesse S Boehm
• Target Validation in Cancer Drug Discovery: Why It Matters - Lenka Munoz
• Cu-Later AML:Inhibition of Heme Biosynthesis Triggers Cuproptosis in Acute Myeloid Leukaemia - Alexander C Lewis
• Targeting a mito-ER stress-sensing ubiquitin complex collapses organellar stress tolerance to force BCL-2/X_L addiction in blood cancers - Thomas E Lew

Session Sponsor

• Genomic, host, and microenvironmental determinants of cancer progression - Christina Curtis
• Tracking and predicting brain metastasis in breast - Delphine Merino
• The Evolving Microenvironment: What Drives Checkpoint Response? - Melvin Chin
• Rewiring Hormone Therapy: Efficacy and Tolerability of High-Dose Testosterone in Advanced Prostate Cancer - Mitchell Lawrence
• Single-cell analysis of telomere maintenance mechanisms in cancer - Ran Xu

Session Sponsors

• Widespread alterations in 3’UTR processing regulate oncogene expression and cancer development - Yvonne Tay
• BCL-XL and MCL-1 determine cell fate after activation of the tumour suppressor TP53/TRP53 - Shuai Huang
• Fibroblast-derived TGFβ3 is a critical stromal cue for T cells to maintain tissue residency and anti-tumor function - Sunny Z. Wu

Session Sponsors

• Lineage Plasticity: An Emerging Mechanism of Acquired Resistance to Cancer Therapy - Charles L Sawyers

Session Sponsor

Best Poster Award Sponsor